Vapogenix is a clinical stage company developing a new class of analgesics based on formulations of volatile anesthetics to treat a variety of localized painful conditions
Their pipeline includes:
AWARD- a topical analgesic used to reduce wound pain associated with ulcerous, traumatic wounds and burns
RAFT- a quick acting topical analgesic for use on intact skin and mucous membranes, with much faster onset of action than competing lidocaine- based products
TAIM- targets alleviating localized inflammatory and muscular pain
Value Provided by Frontcourt
Engaged to raise Series C Funding Round to continue clinical development and initiate commercialization
Advised on amount of need/raise
Assisted in creation of focused clinical and commercial strategy
Created and implemented a Public Relations strategy
Managed inbound strategic M&A interest
Introduced leading pain management KOLs
Introduced key contacts at several potential customer accounts including the VA
Frontcourt identified and structured participation from value-added investors including a major participation from a billion-dollar family office
Identified and introduced value added Board Members
